Brief: Sigilon Therapeutics Announces Acceptance Of Clinical Trial Application In The Uk For Sig-005 For The Treatment Of Mucopolysaccharidosis Type I
09/09/2021 13:14
Sept 9 (Reuters) - Sigilon Therapeutics Inc SGTX.O :
* SIGILON THERAPEUTICS ANNOUNCES ACCEPTANCE OF CLINICAL
TRIAL
APPLICATION IN THE UK FOR SIG-005 FOR THE TREATMENT OF
MUCOPOLYSACCHARIDOSIS TYPE I
Source text for Eikon: ID:nGNX9qzP8l
Further company coverage: SGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sigilon Therapeutics
See all newsSigilon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Sigilon Therapeutics Inc expected to post a loss of $4.71 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Micron, Greenbrier, Immunome
Sigilon jumps on Eli Lilly's buyout deal to expand diabetes treatments
U.S. STOCKS ON THE MOVE-Sigilon, Netflix, RenovoRx